Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Phio Pharmaceuticals ( (PHIO) ).
On January 20, 2026, Phio Pharmaceuticals reported pathology and safety data from all five cohorts in its Phase 1b intratumoral PH-762 dose-escalation trial in cutaneous carcinomas, showing favorable safety and tolerability across a 20-fold dose range with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects. Among 20 patients with cSCC, 14 were pathologic responders, including 10 with complete responses (100% clearance), two with major responses (over 90% clearance) and two with partial responses (over 50% clearance), contributing to a 70% overall response rate for squamous cell carcinomas, while one patient with metastatic Merkel cell carcinoma achieved a partial response and no patients experienced disease progression, positioning PH-762 as a promising non-surgical candidate in skin cancer treatment and informing the design of follow-on clinical trials.
The most recent analyst rating on (PHIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these, recent corporate developments are positive (regulatory progress, trial milestones, and financing), but not enough to overcome the current fundamentals and trend.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company focused on immuno-oncology, advancing its proprietary INTASYL gene-silencing platform to enhance immune cell-mediated cancer killing. The company’s lead program, PH-762, is a PD-1–silencing INTASYL compound in a Phase 1b trial targeting cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma, with the goal of offering a potential non-surgical treatment option for skin cancers.
Average Trading Volume: 3,092,221
Technical Sentiment Signal: Sell
Current Market Cap: $12.27M
See more data about PHIO stock on TipRanks’ Stock Analysis page.